The genetic liability for insomnia is associated with lower amount of slow wave sleep in young and healthy individuals
Pouya
Ghaemmaghami1*,
Vincenzo
Muto1, 2,
Mathieu
Jaspar1, 2, 3,
Christelle
Meyer1, 2,
Mahmoud
Elansary3,
Maxime
VanEgroo1,
Christian
Berthomier4,
Eric
Lambot1, 2,
Marie
Brandewinder4,
Andre
Luxen1,
Christian
Degueldre1,
Eric
Salmon1, 3, 5,
Simon
N.
Archer6,
Christophe
Phillips1, 7,
Derk-Jan
Dijk6,
Danielle
Posthuma8,
Eus
Van Someren8,
Fabienne
Collette1, 3,
Michel
Georges3,
Pierre
Maquet1, 2, 5 and
Gilles
Vandewalle1, 2
-
1
GIGA-Cyclotron Research Center In Vivo Imaging, University of Liege, Belgium
-
2
Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Belgium
-
3
Université de Liège, Belgium
-
4
Other
-
5
Department of Neurology, University Hospital Liège, Belgium
-
6
Surrey Sleep Research Centre, University of Surrey, United Kingdom
-
7
GIGA-In silico Medicine, University of Liège, Belgium
-
8
Netherlands Institute for Neuroscience (KNAW), Netherlands
Introduction. Identifying risk factors for insomnia in individuals that are likely to develop insomnia is needed to develop prevention strategies. Novel genetic tools using results of large case-control genome wide association studies (GWAS) allow to predict the liability for complex diseases based on full-genome common genetic variations. Here, we applied such tools to assess the link between the genetic liability of developing insomnia and sleep phenotypes in young and healthy adults not reporting any sleep complaint.
Methods. Electroencephalography was recording during 8h baseline sleep in 360 healthy young male volunteers with normal sleep (aged 22.09 y ± 2.71). Sleep architecture, the percentage and latency of each sleep stage, and the total number, hourly rate and mean duration of awakenings were extracted from automatic sleep scoring (Aseega, Physip). Blood samples were collected in all participants to assess common Single Nucleotide Polymorphisms (SNPs) over the entire genome. Individual liability for insomnia was computed based on whole genome SNPs using the summary-statistics of a case-control GWAS seeking for genetic determinants of insomnia (Hammerschlag et al. Nat Genet 2017;49:1584–1592, https://ctg.cncr.nl/software/summary_statistics).
Results. Generalized linear mixed model reveal significant associations of one's genetic risk score for insomnia with the percentage of sleep stage 2 (r = 0.13, p <0.05) and the percentage of sleep stage 3 (r = -0.12, p < 0.05). These results suggest that higher liability for insomnia is associated with lower percentage of slow wave sleep while it is associated with higher percentage of lighter sleep. The results remain significant after adjusting for age.
Conclusion. These results show that individual genetic liability for insomnia is linked to sleep lower amount of what is considered most important to dissipate sleep need (i.e. slow wave sleep) in young and healthy individuals. These findings could help identifying novel prevention targets for insomnia.
Acknowledgements
FNRS, ULiège, ARC, FEDER, Welbio, FMRE, Clerdent Foundation
Keywords:
insomnia,
Sleep,
EEG,
Genetics,
aging
Conference:
Belgian Brain Congress 2018 — Belgian Brain Council, LIEGE, Belgium, 19 Oct - 19 Oct, 2018.
Presentation Type:
e-posters
Topic:
NOVEL STRATEGIES FOR NEUROLOGICAL AND MENTAL DISORDERS: SCIENTIFIC BASIS AND VALUE FOR PATIENT-CENTERED CARE
Citation:
Ghaemmaghami
P,
Muto
V,
Jaspar
M,
Meyer
C,
Elansary
M,
VanEgroo
M,
Berthomier
C,
Lambot
E,
Brandewinder
M,
Luxen
A,
Degueldre
C,
Salmon
E,
Archer
SN,
Phillips
C,
Dijk
D,
Posthuma
D,
Van Someren
E,
Collette
F,
Georges
M,
Maquet
P and
Vandewalle
G
(2019). The genetic liability for insomnia is associated with lower amount of slow wave sleep in young and healthy individuals.
Front. Neurosci.
Conference Abstract:
Belgian Brain Congress 2018 — Belgian Brain Council.
doi: 10.3389/conf.fnins.2018.95.00069
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
23 Aug 2018;
Published Online:
17 Jan 2019.
*
Correspondence:
Dr. Pouya Ghaemmaghami, GIGA-Cyclotron Research Center In Vivo Imaging, University of Liege, Liège, Liège, 4000, Belgium, ghaemmaghami.pouya@gmail.com